Cargando…

Time for the ethical management of COVID-19 vaccines

The ethical distribution of life-saving medical and public health interventions to vulnerable groups has often been overlooked. Valuation of life linked to an individual's country of origin, the pharmaceutical industry's prioritisation of profit, the exploitation of vulnerable groups in cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Binagwaho, Agnes, Mathewos, Kedest, Davis, Sheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096324/
https://www.ncbi.nlm.nih.gov/pubmed/33961810
http://dx.doi.org/10.1016/S2214-109X(21)00180-7
_version_ 1783688137558458368
author Binagwaho, Agnes
Mathewos, Kedest
Davis, Sheila
author_facet Binagwaho, Agnes
Mathewos, Kedest
Davis, Sheila
author_sort Binagwaho, Agnes
collection PubMed
description The ethical distribution of life-saving medical and public health interventions to vulnerable groups has often been overlooked. Valuation of life linked to an individual's country of origin, the pharmaceutical industry's prioritisation of profit, the exploitation of vulnerable groups in clinical trials, and the resulting hesitancy towards drugs and vaccines have, among other factors, made the human right to health unattainable for many people. The COVID-19 pandemic presents itself as an opportunity to reverse this long-standing trajectory of unethical practices in global health. By ensuring the ethical inclusion of vulnerable groups in the vaccine development process and making a safe, effective vaccine accessible to all, pharmaceutical companies, governments, and international organisations can usher in a new era of global health that relies solely on ethical decision making.
format Online
Article
Text
id pubmed-8096324
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-80963242021-05-05 Time for the ethical management of COVID-19 vaccines Binagwaho, Agnes Mathewos, Kedest Davis, Sheila Lancet Glob Health Viewpoint The ethical distribution of life-saving medical and public health interventions to vulnerable groups has often been overlooked. Valuation of life linked to an individual's country of origin, the pharmaceutical industry's prioritisation of profit, the exploitation of vulnerable groups in clinical trials, and the resulting hesitancy towards drugs and vaccines have, among other factors, made the human right to health unattainable for many people. The COVID-19 pandemic presents itself as an opportunity to reverse this long-standing trajectory of unethical practices in global health. By ensuring the ethical inclusion of vulnerable groups in the vaccine development process and making a safe, effective vaccine accessible to all, pharmaceutical companies, governments, and international organisations can usher in a new era of global health that relies solely on ethical decision making. The Author(s). Published by Elsevier Ltd. 2021-08 2021-05-04 /pmc/articles/PMC8096324/ /pubmed/33961810 http://dx.doi.org/10.1016/S2214-109X(21)00180-7 Text en © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Viewpoint
Binagwaho, Agnes
Mathewos, Kedest
Davis, Sheila
Time for the ethical management of COVID-19 vaccines
title Time for the ethical management of COVID-19 vaccines
title_full Time for the ethical management of COVID-19 vaccines
title_fullStr Time for the ethical management of COVID-19 vaccines
title_full_unstemmed Time for the ethical management of COVID-19 vaccines
title_short Time for the ethical management of COVID-19 vaccines
title_sort time for the ethical management of covid-19 vaccines
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096324/
https://www.ncbi.nlm.nih.gov/pubmed/33961810
http://dx.doi.org/10.1016/S2214-109X(21)00180-7
work_keys_str_mv AT binagwahoagnes timefortheethicalmanagementofcovid19vaccines
AT mathewoskedest timefortheethicalmanagementofcovid19vaccines
AT davissheila timefortheethicalmanagementofcovid19vaccines